Yang Li, Zhu Yuanhang, Bai Yang, Zhang Xiaoan, Ren Chenchen
Department of Gynecology and Obstetrics, The Third Affiliate Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Radiology, The Third Affiliate Hospital of Zhengzhou University, Zhengzhou, Henan, China.
J Cancer Res Ther. 2017;13(4):613-620. doi: 10.4103/jcrt.JCRT_56_17.
The aim is to evaluate the clinical application value and correlation with cervical lesions' progression of human papillomavirus (HPV) E6/E7 mRNA test in women with atypical squamous cells of undetermined significance (ASCUS/borderline) or low-grade squamous intraepithelial lesions (LSILs/mild dyskaryosis) cytological abnormalities.
A meta-analysis was conduct by searching China National Knowledge Infrastructure (1979-2016), Wanfang Date (1998-2016), VIP (1989-2016), PubMed (1950-2016), Web of Science (1950-2016) and Elsevier Science Direct (1998-2016), for studies on effect of HPV E6/E7 mRNA detection in women with ASCUS/LSIL/dyskaryosis. Study selection and appraisal were conducted independently by three authors, according to inclusive and exclusive criteria. Then, a meta-analysis was performed using the RevMan4.2 software. The subgroups analysis was conducted according to women's initial HPV DNA test results.
Six articles with a total of 1024 subjects were included in the study. It was concluded that a positive HPV E6/E7 mRNA tested result have a higher risk of progressing to CIN2+ in future 2 years than a negative result. The pooled relative risk (RR) is 3.08, (95% confidence interval [CI] = 1.57-6.07, P < 0.05). The same situation was also observed in the subgroup of HPV DNA tested positive group and HPV DNA tested unlimited group. The pooled RR value of the two subgroups was, respectively, 1.98, (95% CI = 1.19-1.19, P < 0.05) and 7.58, (95% CI = 3.64-3.64, P < 0.05).
A positive HPV E6/E7 mRNA testing result suggested the women with ASCUS, or LSIL Pap smear was in a truly dangerous position, which is an adverse prognostic factor. It suggested that cervical lesions stay in a progressing status and these women should be referred for colposcopy and strengthen follow-up promptly. Whereas, women with a negative HPV E6/E7 mRNA testing result can increase follow-up interval, by comprehensively considering their situation, thus, avoiding unnecessary colposcopy and reducing the rate of colposcopy and biopsy.
评估人乳头瘤病毒(HPV)E6/E7 mRNA检测在意义不明确的非典型鳞状细胞(ASCUS/边界线)或低度鳞状上皮内病变(LSILs/轻度核异质)细胞学异常女性中的临床应用价值及其与宫颈病变进展的相关性。
通过检索中国知网(1979 - 2016年)、万方数据(1998 - 2016年)、维普资讯(1989 - 2016年)、PubMed(1950 - 2016年)、Web of Science(1950 - 2016年)和爱思唯尔科学Direct(1998 - 2016年),进行一项荟萃分析,以研究HPV E6/E7 mRNA检测对ASCUS/LSIL/核异质女性的影响。由三位作者根据纳入和排除标准独立进行研究选择和评估。然后,使用RevMan4.2软件进行荟萃分析。根据女性最初的HPV DNA检测结果进行亚组分析。
该研究纳入了6篇文章,共1024名受试者。结果表明,HPV E6/E7 mRNA检测结果为阳性的女性在未来2年内进展为CIN2+的风险高于阴性结果。合并相对风险(RR)为3.08,(95%置信区间[CI] = 1.57 - 6.07,P < 0.05)。在HPV DNA检测阳性组和HPV DNA检测结果未知组的亚组中也观察到了相同情况。两个亚组的合并RR值分别为1.98,(95% CI = 1.19 - 1.(此处原文有误,推测为1.98)19,P < 0.05)和7.58,(95% CI = 3.64 - 3.64,P < 0.05)。
HPV E6/E7 mRNA检测结果为阳性表明ASCUS或LSIL巴氏涂片检查的女性处于真正危险的境地,这是一个不良预后因素。这表明宫颈病变处于进展状态,这些女性应立即转诊进行阴道镜检查并加强随访。而HPV E6/E7 mRNA检测结果为阴性的女性可以通过综合考虑其情况增加随访间隔,从而避免不必要的阴道镜检查并降低阴道镜检查和活检率。